Subsequent studies showed that the MEK1/2 inhibitor selumetinib synergised with ABT‐263 to kill BRAF‐ and RAS‐mutant colorectal cancer and melanoma cell lines, causing a striking inhibition of long‐term clonogenic survival 60, 85. Here, BRAF is linked to melanoma.